Publications by authors named "R Ramon Sapena"
Article Synopsis
- CPX-351, a drug combining cytarabine and daunorubicin, shows better results than traditional treatments for secondary acute myeloid leukemia and is being tested for its safety and efficacy in related blood disorders.
- A phase 2 trial included patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia, focusing on those in their first-line treatment, while a second cohort was halted due to low patient enrollment.
- The trial's results indicated a strong response rate, with 87% of participants showing improvement after treatment with CPX-351, backed by data collected from 31 patients during the study period.
Purpose: Hydroxyurea (HY) is a reference treatment of advanced myeloproliferative neoplasms. We conducted a randomized phase III trial comparing decitabine (DAC) and HY in advanced myeloproliferative chronic myelomonocytic leukemias (CMML).
Patients And Methods: Newly diagnosed myeloproliferative CMML patients with advanced disease were randomly assigned 1:1 to intravenous DAC (20 mg/m/d days 1-5) or HY (1-4 g/d) in 28-day cycles.
Article Synopsis
- - The EUROPE phase 2 trial examined how well biomarkers predict the effectiveness of romiplostim (ROM) treatment for patients with lower-risk myelodysplastic neoplasms (LR-MDS) and low platelet counts, involving 77 patients from the EMSCO network.
- - Out of the participants, 42% showed significant improvements in platelet counts, lasting a median of 340 days, while other types of responses (neutrophil and erythroid) were much less common.
- - The study found that while certain mutations (like SRSF2) and baseline hemoglobin levels were linked to positive responses, ROM treatment did not affect the progression of genetic mutations in patients, confirming its safety and efficacy.